ARWR Arrowhead Pharmaceuticals reports topline results from phase 3 shasta-3 and shasta-4 studies of plozasiran in patients with severe hype
ARWR Arrowhead Pharmaceuticals reports topline results from phase 3 shasta-3 and shasta-4 studies of plozasiran in patients with severe hypertriglyceridemia